Cue Biopharma Inc Stock Price, News & Analysis

Cue Biopharma (CUE) has announced the appointment of Patrick Verheyen to its Board of Directors, bringing over 35 years of experience from Janssen Pharmaceutical. Verheyen's expertise in business development and M&A is expected to enhance Cue's corporate growth and current drug candidates, CUE-101 and CUE-102. Daniel Passeri, CEO of Cue Biopharma, expressed enthusiasm for Verheyen's insights, aiming to broaden the company’s strategic initiatives in immunotherapy for autoimmune diseases and cancer. Verheyen's past achievements include leading significant acquisitions at Janssen, which expanded its pipeline and established a global innovation presence.

On March 21, 2023, Cue Biopharma reported significant advancements in its clinical initiatives and financial results for 2022. The FDA accepted its IND application for CUE-102 targeting WT1-expressing cancers and started a Phase 1 trial. CUE-101 received Fast Track Designation for HPV+ head and neck cancers. The 2022 collaboration revenue dipped to $1.2 million from $14.9 million in 2021, while net losses increased to $53 million, affected by reduced research funding and expenses. However, cash reserves rose to $76.3 million, expected to support operations until late 2024. The company aims to present updated data on its oncology programs in upcoming conferences.

Cue Biopharma (Nasdaq: CUE) will host a conference call and webcast on March 21, 2023, at 4:30 p.m. EDT to discuss business and clinical updates. The session will detail ongoing trials of CUE-101, an IL-2-based biologic targeting HPV+ head and neck cancer, and CUE-102 for WT1-expressing cancers. The company also plans to discuss its partnership with Ono Pharmaceutical aimed at advancing CUE-401 for autoimmune diseases. Investors can join via phone or webcast, with registration available on the company's website.

BOSTON, March 1, 2023 (GLOBE NEWSWIRE) -- Cue Biopharma, a clinical-stage biopharmaceutical company, will participate in two healthcare investor conferences this March: the Cowen 43rd Annual Health Care Conference (March 6-8) and the Oppenheimer 33rd Annual Healthcare Conference (March 13-15). The presentations will showcase advancements from the IL-2-based CUE-100 series of biologics, including details on ongoing Phase 1 trials for its drug candidate, CUE-101, targeting HPV+ cancers, and CUE-102 for Wilms’ Tumor 1 positive cancers. The company also announced a partnership with Ono Pharmaceutical to advance CUE-401 for autoimmune diseases.

Cue Biopharma has announced a collaboration with Ono Pharmaceutical for the development of CUE-401, a bispecific protein targeting regulatory T cells to treat autoimmune and inflammatory diseases. This partnership marks a significant step in Cue Biopharma's strategy, providing funding and resources to advance CUE-401 towards clinical trials. Ono will cover all research costs and, upon exercising its option to license CUE-401, Cue Biopharma could receive up to $220 million in milestone payments along with tiered royalties. This collaboration allows Cue Biopharma to retain co-development rights in the U.S.

On February 16, 2023, Cue Biopharma announced a strategic collaboration with Dr. Michael Dustin's lab to explore the mechanisms behind its Immuno-STAT platform, designed to engage disease-specific T cells. The company will present findings at the 67th Biophysical Society Annual Meeting from February 18-22, 2023. The research supports the differentiated action of Immuno-STAT biologics, particularly the CUE-100 series, in selectively activating ‘killer’ T cells while minimizing off-target effects. Clinical progress of CUE-101 in HPV+ head and neck cancer shows promising T cell activation results, indicating potential for broader cancer treatment applications.

BOSTON, Feb. 16, 2023 – Cue Biopharma announced the appointment of Dr. Rafi Ahmed to its Scientific Advisory Board. Dr. Ahmed is a distinguished immunologist recognized for his research on T cell responses in viral infections and cancer. His insights are expected to bolster Cue's IL-2-based CUE-100 series targeting tumor-specific T cells, showcasing promising clinical data with CUE-101 for head and neck cancer and ongoing trials for CUE-102. Dr. Ahmed, also the Director of the Emory Vaccine Center, expressed excitement about contributing to Cue's innovative Immuno-STAT™ platform, aiming to advance targeted cancer therapies with fewer side effects.

BOSTON, Feb. 01, 2023 (GLOBE NEWSWIRE) -- Cue Biopharma, a clinical-stage biopharmaceutical company, announced that its President and Chief Scientific Officer, Anish Suri, Ph.D., will participate in two upcoming scientific conferences in February: Immuno-Oncology 360 in New York and the FASEB Catalyst Conference virtually. Dr. Suri will present an overview of the company’s Immuno-STAT™ platform and its IL-2-based CUE-100 biologics, designed for selective targeting of tumor-specific T cells. The presentations are scheduled for February 7 and February 9, 2023. Cue Biopharma focuses on developing biologics to engage disease-specific T cells without broad systemic modulation.

On January 23, 2023, Cue Biopharma announced the promotion of Matteo Levisetti, M.D., to Chief Medical Officer (CMO), effective January 17, 2023. Dr. Levisetti, previously the senior vice president of clinical development, succeeds Kenneth Pienta, M.D., who will transition to a clinical advisory role. CEO Daniel Passeri expressed confidence in Dr. Levisetti's ability to lead the company’s oncology pipeline, particularly the development of CUE-101 and CUE-102. Dr. Levisetti has a robust background in clinical development, having held leadership roles in various pharmaceutical companies. Cue Biopharma focuses on innovative injectable biologics designed to engage and modulate T cells for cancer treatment.